Beijing SL Pharmaceutical Co., Ltd.

Shenzhen Stock Exchange 002038.SZ

Beijing SL Pharmaceutical Co., Ltd. Shareholders' Equity for the year ending December 31, 2023: USD 817.02 M

Beijing SL Pharmaceutical Co., Ltd. Shareholders' Equity is USD 817.02 M for the year ending December 31, 2023, a 3.11% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Beijing SL Pharmaceutical Co., Ltd. Shareholders' Equity for the year ending December 31, 2022 was USD 792.38 M, a -5.21% change year over year.
Beijing SL Pharmaceutical Co., Ltd. Shareholders' Equity for the year ending December 31, 2021 was USD 835.92 M, a 9.69% change year over year.
Beijing SL Pharmaceutical Co., Ltd. Shareholders' Equity for the year ending December 31, 2020 was USD 762.11 M, a 10.38% change year over year.
Beijing SL Pharmaceutical Co., Ltd. Shareholders' Equity for the year ending December 31, 2019 was USD 690.46 M, a 5.58% change year over year.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

Shenzhen Stock Exchange: 002038.SZ

Beijing SL Pharmaceutical Co., Ltd.

CEO	Dr. Mingbo Xu Ph.D.
IPO Date	Sept. 9, 2004
Location	China
Headquarters	Building 1, Bitongyuan
Employees	856
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, researches, develops, produces, and markets genetic engineering and related drugs in the People's Republic of China and internationally. The company's finished formulations includes temozolomide; arsenic trioxide; lenalidomide; docetaxel; paclitaxel; filgrastim Recombinant human granulocyte colony-stimulating factor; recombinant human interleukin-11; recombinant human interleukin-2; thymopentin; vinorelbine bitartrate; hydroxyl-camptothecine; nimustine hydrochloride; asparaginase; PEG L-asparaginase; calcium foliate; recombinant human basic fibroblast growth factor; ciclosporin; mycophenolate mofetil dispersible; ornidazole; adefovir dipivoxil; levofloxacin hydrochloride; azithromycin; ribavirin; tenofovir disoproxil fumarate; valacylovir hydrochloride; lysozyme; stavudine; tropisetron hydrochloride; granisetron hydrochloride; omeprazole; ademetionine 1,4-butanedisulfonate; glutathione; enoxaparin sodium; coenzyme complex; ginkgo biloba extract; simvastatin; telmisartan; naftopidil; nicergoline; zaleplon; cytidine disodium triphosphate; febuxostat; risedronate sodium; loratadine dispersible; somatostatin; octreotide acetate; calcitonin (salmon); paracetamol and tramadol hydrochloride; and etodolac. It also offers active pharmaceutical ingredients. The company was formerly known as Beijing BaiLuyuan Bio-Pharmaceutical Co., Ltd and changed its name to Beijing SL Pharmaceutical Co., Ltd. in 1998. Beijing SL Pharmaceutical Co., Ltd. was founded in 1994 and is based in Beijing, the People's Republic of China.

Key trends

Past 5 years